• Explore /
  • Poster
  • / DREAMM-9: Phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM).

DREAMM-9: Phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM).

Abstract Video & Slides Poster

Authors

Saad Usmani

Saad Zafar Usmani

Levine Cancer Institute, Charlotte, NC

Saad Zafar Usmani , Evangelos Terpos , Wojt Janowski , Hang Quach , Sarah West , Danae Williams , Elisha J. Dettman , Geraldine Ferron-Brady , Katarina Luptakova , Ira Gupta

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT04091126

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS8556)

DOI

10.1200/JCO.2020.38.15_suppl.TPS8556

Abstract #

TPS8556

Poster Bd #

456

Abstract Disclosures

Similar Posters

First Author: Saad Zafar Usmani

First Author: Shaji Kumar

First Author: Sonja Zweegman

First Author: Pieter Sonneveld